Evotec SE

EVTA

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,766

Stocks News & Analysis

stocks

Market too pessimistic about unloved ASX health care share

Our analysts believe a long-term margin recovery is underway.
stocks

Two overvalued ASX shares to avoid

Both shares trade at a significant premium to our fair value.
stocks

Materially undervalued ASX tech share

Long reinvestment runway supports our thesis on ASX technology company.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,901.204.60-0.05%
CAC 407,959.6721.40-0.27%
DAX 4023,464.63225.450.97%
Dow JONES (US)47,112.45867.041.87%
FTSE 1009,548.038.320.09%
HKSE25,972.2677.710.30%
NASDAQ23,025.59752.513.38%
Nikkei 22549,605.57946.051.94%
NZX 50 Index13,612.02131.590.98%
S&P 5006,765.8860.760.91%
S&P/ASX 2008,610.205.80-0.07%
SSE Composite Index3,873.753.720.10%

Market Movers